GYRE — Gyre Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $650.16m
- $633.98m
- $116.59m
Annual income statement for Gyre Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.34 | 0.794 | 113 | 106 | 117 |
| Cost of Revenue | |||||
| Gross Profit | -0.042 | -0.004 | 109 | 102 | 111 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 95.2 | 9.22 | 181 | 89.6 | 105 |
| Operating Profit | -87.9 | -8.43 | -67.2 | 16.2 | 11.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -87.9 | -7.89 | -77 | 23.2 | 14.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -87.9 | -8.24 | -85.5 | 17.9 | 9.88 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -87.9 | -8.24 | -92.9 | 12.1 | 5.03 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -87.9 | -8.24 | -92.9 | 12.1 | 5.03 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -43 | -4.51 | -0.116 | 0.119 | 0.049 |
| Special Dividends per Share |